Protective effects of ursodeoxycholic acid on ceftriaxone-induced hepatic injury in rats  by Alhumaidha, Khaled A. et al.
Bulletin of Faculty of Pharmacy, Cairo University (2014) 52, 45–50Cairo University
Bulletin of Faculty of Pharmacy, Cairo University
www.elsevier.com/locate/bfopcu
www.sciencedirect.comORIGINAL ARTICLEProtective eﬀects of ursodeoxycholic acid
on ceftriaxone-induced hepatic injury in rats* Corresponding author. Tel.: 20 1092412006.
E-mail address: alhmudh@yahoo.com (K.A. Alhumaidha).
Peer review under responsibility of Faculty of Pharmacy, Cairo
University.
Production and hosting by Elsevier
1110-0931 ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
http://dx.doi.org/10.1016/j.bfopcu.2014.02.002
Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.Khaled A. Alhumaidha *, Sally A. El-Awdan, Wafaa I. El-Iraky,
Ezz-El-Din S. El-DensharyCairo University, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kasr El-Eini Street, Cario, EgyptReceived 21 December 2012; accepted 8 February 2014
Available online 6 March 2014KEYWORDS
Ceftriaxone;
Ursodeoxycholic acid;
Hepatotoxicity;
LiverAbstract Ceftriaxone is a broad-spectrum semisynthetic cephalosporin antibiotic that causes
partial damage in the liver manifested by transient elevation in some biochemical parameters. In this
study, our aim was to investigate the use of ursodeoxycholic acid (UDCA) in prevention of the
hepatotoxic effect and biochemical changes induced by ceftriaxone in rats. Rats were divided into
six groups (control, UDCA 20 mg/kg, ceftriaxone 180 mg/kg, UDCA+ ceftriaxone 180 mg/kg, cef-
triaxone 360 mg/kg, and UDCA+ ceftriaxone 360 mg/kg). Ceftriaxone was injected intraperitone-
ally, and UDCA was given orally daily for four consecutive weeks. Then liver functions (serums
AST, ALT, ALP, direct bilirubin, and total protein) were assessed. Histopathological examination
was performed. Treatment of animals with ceftriaxone caused elevated activities of serum alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) as well as total bilirubin level. These
elevations in liver enzymes were decreased by combination ceftriaxone with UDCA. In addition, cef-
triaxone caused a signiﬁcant increase in malondialdehyde (MDA) and nitric oxide (NO) content but
signiﬁcant decrease in glutathione (GSH) content. Combination of UDCA and ceftriaxone resulted
in a signiﬁcant decrease in MDA, NO content and signiﬁcantly elevated GSH content. It could be
concluded that UDCA acts as an effective hepatoprotective agent against liver dysfunction caused
by ceftriaxone, and this effect might be related to its antioxidant properties. Hepatic functions should
be monitored, and the dose should be adjusted during ceftriaxone therapy.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Liver injury caused by drugs ranges from mild biochemical
abnormalities to acute and chronic liver failure. The majority
of adverse liver reactions is idiosyncratic, and occurs in most
instances 5–90 days after the causative medication was last
taken.1
Some antibiotics are considered a common cause of drug-
induced liver injury.2 Hepatotoxicity that occurs is usually
46 K.A. Alhumaidha et al.asymptomatic, transient and associated with hepatic
impairment.3 Ceftriaxone is a broad-spectrum parenteral
cephalosporin with potent activity against gram-positive and
gram-negative bacteria.4 It widely used, because of its pro-
longed terminal half-life that allows its prescription as a single
dose per day.5 Hepatotoxicity caused by ceftriaxone appears
after 9–11 days.6,7 Previous studies have reported high aspar-
tate aminotransferase (ALT) and alanine aminotransferase
(AST) activities with the administration of ceftriaxone.8,9
Ceftriaxone causes partial damage in the liver as a result of
transient elevation in some biochemical parameters such as
AST, ALT, total bilirubin, cholesterol, triglyceride (TG)
and Low-density lipoprotein (LDL) as well as transient
decrease in albumin and High-density lipoprotein (HDL)
concentrations.10
Ursodeoxycholic acid (UDCA) is one of the secondary bile
acids, which are metabolic byproducts of intestinal bacteria
and it has antioxidative properties.11 It has extensively been
used in clinical practice as a ﬁrst-line therapy for cholestatic li-
ver diseases. However, in recent years, a number of clinical and
experimental data have shown the beneﬁcial effects of UDCA
in noncholestatic liver injury. UDCA prevents damaging the
liver mitochondrial functions and preserve its structure in
chronic alcohol intoxication.12 UDCA has been conﬁrmed to
improve liver functions in primary biliary cirrhosis (PBC), pri-
mary sclerosing cholangitis, pediatric cholestatic disorders,
and cystic ﬁbrosis.13
UDCA has been reported to protect against hepatotoxicity
caused by amoxicillin-clavulanic acid in rats through its anti-
oxidant properties.14 In addition, another study showed that
UDCA has protective effect against isoniazid plus rifampicin
induced liver injury in mice.15 The mechanism of the UDCA
hepatoprotective effect could be mediated by displacement of
toxic bile acids from the bile acid pool as well as choleretic,
immunomodulatory and cytoprotective properties.16
The present work has been designed to evaluate the poten-
tial role of UDCA in prevention of hepatotoxic effect and bio-
chemical alterations that are induced by ceftriaxone in albino
male rats.
2. Materials and methods
2.1. Animals
Adult male Wistar albino rats (150–200 g) were obtained from
the animal house colony of the National Research Center
(Giza, Egypt). Rats were placed in a temperature
(22 ± 2 C) and humidity (50 + 5%) controlled room in
which 12 h light/dark cycles were maintained for one week be-
fore the start of the experiment. A standard diet and tap water
were provided ad libitum. This study was approved by the
Animal Research Ethics Committee, Faculty of Pharmacy,
Cairo University (PT 309).
2.2. Drugs
UDCA was purchased from SEDICO (6th October, Egypt)
and was dissolved in 1% tween 80 shortly before administra-
tion to animals. Ceftriaxone was obtained from Novartis
Pharma Company (Cairo, Egypt) and was freshly dissolved
in distilled water immediately before administration. Otherchemicals were obtained from local sources and were of analyt-
ical grade.
2.3. Experimental design
The rats were divided randomly into six experimental groups,
each consisting of eight rats, that were treated as follows:
group 1 received vehicle and served as a control, group 2
received UDCA (20 mg/kg), group 3 received ceftriaxone
(180 mg/kg), group 4 received combined oral doses of UDCA
20 mg/kg and ceftriaxone 180 mg/kg, group 5 received ceftri-
axone (360 mg/kg) and ﬁnally group 6 received combined oral
doses of UDCA 20 mg/kg and ceftriaxone (360 mg/kg). Ceftri-
axone was i.p. injected while UDCA was orally administered
for 4 weeks.
At the end of the experiment blood samples were collected
from the retro-orbital plexus and used for serum separation.
All the rats were sacriﬁced by decapitation and the livers of
rats were immediately dissected out. Part of the liver tissues
was homogenized in ice-cold 0.9% w/v saline using a homog-
enizer to obtain 20% homogenate. Aliquots of the liver
homogenate were stored at 4 C prior to biochemical analy-
sis. The other part of the liver was preserved in 10% formalin
solution for histopathological examination.
2.4. Determination of biochemical parameters
Hepatic enzymes in the serum such as AST and ALT were used
as biochemical markers for hepatotoxicity and assayed by the
method of Reitman and Frankel.17 Serum alkaline phospha-
tase (ALP) was determined according to the method of
Belﬁeld and Goldberg18 using colorimetric kit obtained from
Diamond Co., Egypt. Total serum bilirubin was determined
spectrophotometrically according to the method of Walter
and Gerade.19
Glutathione (GSH) content was measured spectrophoto-
metrically using the method of Sedlak and L’ Hanus.20 Results
were calculated as lM/g tissue. Lipid peroxidation was deter-
mined in liver homogenates as thiobarbituric acid reactive spe-
cies (TBARS) using malondialdehyde (MDA) as a reference
standard of oxidative stress according to the method described
by Buege and Aust21 and measured in nmol/g.22 Nitric oxide
was determined according to the method described by Miran-
da et al.23
2.5. Preparation of sections for histopathological examination
Liver was dissected out and the liver samples were excised
from the experimental animals of each group and were ﬁxed
in 10% saline buffered formalin. Tissues were then embedded
in parafﬁn subsequently; 5 lM sections were cut on a micro-
tome and examined microscopically for the evaluation of his-
topathological changes.
2.6. Statistical analysis
Data are presented as mean ± SE. Statistical analysis of the
data was carried out using one way analysis of variance
(ANOVA) followed by Tukey’s test for post hoc analysis.
Statistical signiﬁcance was acceptable to a level of p< 0.05.
Protective effects of ursodeoxycholic acid 47Data analysis was accomplished using the software program
graphpad prism (version 5).
3. Results
3.1. Effect of ceftriaxone 180 mg/kg (cef1) and ceftriaxone 360
mg/kg (cef2) with or without UDCA 20 mg/kg on serum levels
of ALT, AST, ALP, total protein, and direct bilirubin
Results of biochemical tests (ALT, AST, ALP, total protein,
and direct bilirubin) are summarized in Table 1. Serum ALT
activity signiﬁcantly increased in rats treated with ceftriaxone
180 mg/kg (cef1) and ceftriaxone 360 mg/kg (cef2) by 40%
and 48% respectively as compared with control group. How-
ever groups which were treated with cef1 + UDCA and ce-
f2 + UDCA showed signiﬁcantly low activity of ALT by
42% and 30% when compared with cef1 and cef2 respectively.
As well groups treated with cef1 and cef2 have signiﬁcantly in-
creased AST activity by 30% and 48% respectively as com-
pared with the control group. Concurrent administration of
cef1 and cef2 simultaneously with UDCA induced a signiﬁcant
decrease in AST activity by 35% and 38% when compared
with groups treated with cef1 and cef2 respectively. ALP activ-
ity in rats treated with cef1 and cef2 was found to be higher
than the control group by 15% and 17% respectively.
However groups which were treated with cef1 + UDCA and
cef2 + UDCA showed signiﬁcantly low activity of ALP by
19% and 14% when compared with cef1 and cef2 respectively.
Total protein and direct bilirubin were signiﬁcantly decreased
in the group treated with cef2 + UDCA by 31% and 37%
respectively when compared with group treated with cef2.
3.2. Effect of ceftriaxone 180 mg/kg (cef1) and ceftriaxone 360
mg/kg (cef2) with or without UDCA 20 mg/kg on hepatic
oxidative stress: GSH, MDA contents, and NO contents
As shown in Table 2, groups were treated with ceftriaxone
180 mg/kg (cef1) and ceftriaxone 360 mg/kg (cef2) showed sig-
niﬁcantly low levels in GSH contents by 20% and 31% respec-
tively as compared with control group and the level of hepatic
GSH in the groups cef1 + UDCA and cef2 + UDCA was
found signiﬁcantly highly elevated by 31% and 57% whenTable 1 Effect of ceftriaxone (cef1) 180 mg/kg and ceftriaxone (cef
20 mg/kg on serum activity of ALT, AST, ALP, direct bilirubin and
Groups Parameters
ALT(U/L) AST(U/L) AL
Control 25.1 ± 2.16 61.5 ± 2.77 326
UDCA(20 mg/kg) 24.3 ± 2.33 52.6 ± 4.34c 359
Cef1 (180 mg/kg) 35.0 ± 1.35a 80.4 ± 5.70a 376
Cef1 + UDCA 20.3 ± 1.22b,c 51.9 ± 3.17b,c 298
Cef2 (360 mg/kg) 37.2 ± 1.62a 91.3 ± 4.361a 382
Cef2 + UDCA 26.1 ± 2.89b,c 55.9 ± 4.414b,c 330
ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP:
All data were expressed as means ± SE (n= 8–10/group).
Data comparison was performed using one way ANOVA followed by Tu
a Signiﬁcantly different from the control group at p< 0.05.
b Signiﬁcantly different from (cef1) group values at p< 0.05.
c Signiﬁcantly different from (cef2) group values at p< 0.05.compared with cef1 and cef2 respectively. Finally, MDA and
nitric oxide contents were signiﬁcantly increased in cef1 and
cef2 groups when compared with the control group and the
levels of MDA and nitric oxide were signiﬁcantly decreased
in the groups treated with cef1 + UDCA, and cef2 + UDCA
when compared with cef1 and cef2 respectively.
3.3. Histopathological study
Histological studies, showed normal hepatic lobular architec-
ture in the liver of rats treated with UDCA 20 mg/kg
(Fig. 2) in comparison with the control group (Fig. 1).
In the Ceftriaxone 180 mg/kg treated group the liver
showed diffuse hydropic degeneration in the hepatocytes of
periportal (peripheral) area (zone 3) with shrinked, dark nuclei
(pyknosis) (Fig. 3). The group treated with ceftriaxone 180
mg/kg in combination with UDCA showed mild focal hydro-
pic degeneration in the periportal area in limited areas in com-
parison with the group treated with ceftriaxone alone (Fig. 4).
Ceftriaxone 360 mg/kg treated rats (group 5) showed nearly
complete lobular degeneration in the form of hydropic degen-
eration of hepatocytes with pyknosis nuclei, sparing a small
area surrounding the central zone (Fig. 5). Group 6 treated
by ceftriaxone 360 mg/kg in combination with UDCA showed
degeneration in hepatocytes of the periportal area with normal
hypatocytes in the central lobular area which were protected
from damage (Fig. 6).
4. Discussion
It is well-known that ceftriaxone is widely used as a third
generation cephalosporin antibiotic that has a broad spectrum
of bactericidal activity.24 However, an increasing number of
evidence indicates that it has risk of elevation of the liver
enzyme, cholestatic abnormalities and liver injury as adverse
effect10,25–28 and the mechanism of its hepatotoxicity appears
to be immunologically mediated.29
UDCA stabilizes the mitochondrial and plasma membranes
of hepatocytes that protect them from various other injuries
and it constitute an antiapoptotic action.30 This protective ef-
fect is probably due to its antioxidant action.31 Previous study
showed that UDCA protected mice from liver injury induced2) 360 mg/kg with or without of ursodeoxycholic acid (UDCA)
total protein.
P(U/L) Direct bilirubin(lmol/l) Total Protein mg/dl
± 7.06 1.04 ± 0.194 8.65 ± 0.570
± 8.62 1.27 ± 0.258 10.3 ± 1.10
± 1.17a 1.31 ± 0.141 8.11 ± 0.379
± 15.8b,c 1.3 ± 0.0609 8.84 ± 0.430
± 6.85a 1.91 ± 0.100a 9.07 ± 0.707
± 16.0c 1.20 ± 0.102c 11.9 ± 0.733a,c
alkaline phosphatase.
key’s Multiple Comparison Test.
Table 2 Effect of ceftriaxone (cef1) 180 mg/kg and ceftriaxone (cef2) 360 mg/kg with or without of ursodeoxycholic acid (UDCA)
20 mg/kg on hepatic Oxidative Stress: GSH, MDA, and NO contents.
Groups Parameters
GSH (lM/g) MDA (nM/mg) NO (lmol/l)
Control 4.56 ± 0.0592 216.5 ± 7.10 420.8 ± 2 8.85
UDCA (20 mg/kg) 4.84 ± 0.237 216.2 ± 11.7b,c 358.9 ± 11.13b,c
Cef1 (180 mg/kg) 3.63 ± 0.0320a 279.8 ± 9.01a 528.3 ± 31.77
Cef1 + UDCA 4.75 ± 0.0793b,c 205.8 ± 4.77b,c 437.6 ± 20.85c
Cef2 (360 mg/kg) 3.14 ± 0.199a 314 ± 19.9a 688.1 ± 35.05a
Cef2 + UDCA 4.93 ± 0.155b,c 237.7 ± 2.43c 480.1 ± 41.94c
GSH: glutathione, MDA: malondialdehyde, NO: nitric oxide.
All data were expressed as means ± SE, (n= 8–10/group).
Data comparison was performed using one way ANOVA followed by Tukey’s Multiple Comparison Test.
a Signiﬁcantly different from the control group at p< 0.05.
b Signiﬁcantly different from (cef1) group values at p< 0.05.
c Signiﬁcantly different from (cef2) group values at p< 0.05.
Figure 1 A photomicrograph of a section in the liver of adult
male albino rat in control group showing; normal central vein and
normally arranged hepatocytes (H&E, ·100).
Figure 2 A photomicrogaph of a section in the liver of rat
treated by Ursodeoxycholic acid (UDCA, 20 mg/kg) showing;
normal hepatic lobular architecture with normal central vein and
portal tract (H&E, ·100).
Figure 3 A photomicrograph of a section in the liver of rat
treated by ceftriaxone 180 mg/kg showing; focal areas of hepato-
cyte hydropic degeneration alternating with areas of normal
hepatocytes (H&E, ·50).
Figure 4 A photomicrogaph of a section in the liver of rat
treated by Ursodeoxycholic acid (UDCA) + ceftriaxone 180
mg/kg showing; mild hydropic degeneration in the periportal
(peripheral) area and normal central lobular area (H&E, ·50).
48 K.A. Alhumaidha et al.by isoniazid plus rifampicin.15 In addition, UDCA acts an
effective hepatoprotective agent against liver dysfunction
caused by the broad spectrum antibiotic combination
amoxicillin-clavulanic acid14 and protected rats from liver in-
jury induced by methotrexate, an immunosuppressant drug.32
The serum bilirubin, AST, ALT, and ALP are the most
sensitive biochemical markers employed in the diagnosis of
hepatic dysfunction.33 In this study we found signiﬁcant
elevation of serum ALT and AST activity in rats treated withceftriaxone which is similar to the results found in previous
studies.10,27,29 However combination of ceftriaxone plus
UDCA causes signiﬁcant improvement in liver function and
signiﬁcant reduction in liver enzyme activities such as ALT
and AST. These results provide evidence that UDCA could
protect against drug-induced liver injury. The normalization
of serum markers by UDCA suggests that it is able to protect
the membrane integrity against ceftriaxone that induces leak-
age of marker enzymes into the circulation. Also in this study
we found that high dosages of ceftriaxone were associated with
higher percentages of hepatocellular enzyme elevations.
Figure 5 A photomicrogaph of a section in the liver of rat
treated Ceftriaxone 360 mg/kg showing; diffuse hydropic degen-
eration in nearly all the lobule (H&E, ·50).
Figure 6 A photomicrogaph of a section in the liver of rat
treated by Ursodeoxycholic acid (UDCA) + ceftriaxone 360
mg/kg showing; normal hepatocytes in the central lobular area
with area of degeneration in periportal area (H&E, ·50).
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be related to hepatic cell damage due to cholestasis and
increased biliary pressure.34,35 In this study we found that
ceftriaxone produced a signiﬁcant increase in ALP and biliru-
bin. The obtained results were similar to those obtained by
others.10,36 Gillian and Gonard37 found that, ceftriaxone,
displaced bilirubin from albumin and increased erythrocyte
bound bilirubin and unbound bilirubin, and should be used
with caution in high risk jaundiced newborns. Administration
of UDCA to rats treated with ceftriaxone markedly reduced
serum ALP (serum cholestatic enzyme), decreased serum bili-
rubin and increased the level of protein suggesting its protec-
tive effect.
Oxidative stress and lipid peroxidation that are mediated by
oxygen free radicals have been implicated as a common link
between chronic liver damage and hepatic ﬁbrosis.38 The
results of our study demonstrated that administration of cef1
and cef2 resulted in markedly signiﬁcant decrease in the
level of hepatic GSH. Conversely, the level of hepatic MDA
(a marker of lipid peroxidation), and NO was obviously
increased. The increase in MDA and NO level was more
pronounced in rats treated with ceftriaxone (cef2) 360 mg/kg
than ceftriaxone (cef1) 180 mg/kg.
We also found that UDCA was able to normalize the ele-
vated biochemical oxidative stress markers; hepatic MDA,
and NO in addition, it restored GSH levels. UDCA exerted
a protective effect against this oxidative injury not only bio-
chemically, but also histopathologically, suggesting that the
tissue damage induced by ceftriaxone (cef2) 360 mg/kg could
be effectively prevented by UDCA.
UDCA signiﬁcantly increased the levels of GSH and thiol-
containing proteins, thereby protecting hepatocytes against
oxidative injury.39 Last studies demonstrated that UDCAinduced the expression of detoxifying enzymes and antioxida-
tive stress genes via the Nrf2 transcriptional pathway
40 and
protective effect of UDCA against different liver injuries was
conﬁrmed by several previous studies.13–15,41
UDCA has a protective role in the secondary biliary cirrho-
sis through counteracting mitochondrial oxidative stress42,43
and the synthesis of endogenous antioxidant defenses, includ-
ing glutathione synthesis and antioxidant enzymes.39 It pro-
tected liver mitochondria from abnormalities induced by
lipid peroxidation and minimized the elevation of lipid perox-
ides induced by hydrogen peroxide.44 The antioxidative
effect45,46 and immunomodulatory effects47,48 of UDCA can
explain its hepatoprotective effects observed in this study.
Histopathological examination in this study conﬁrmed the
biochemical results. Liver specimens obtained from groups
treated with ceftriaxone plus UDCA showed mild hydropic
degeneration in the periportal (peripheral) area and normal
hepatocytes in the central lobular area compared to ceftriax-
one which showed nearly complete lobular degeneration.
5. Conclusion
In conclusion; the results of the present study demonstrate that
UDCA has a hepatoprotective effect against liver injury
caused by ceftriaxone owing to its antioxidant and immuno-
modulatory properties. Further, clinical studies are required
to conﬁrm this effect.
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